Founded Year



Series C | Alive

Total Raised




Last Raised

$300M | 7 mos ago

About Cerebral

Cerebral is a mental health company dedicated to improving access to treatment for anxiety and depression. The company offers ongoing video visits with a prescribing provider, medication and medication delivery if prescribed, and an assigned care manager who is available for regular check-in calls and unlimited messaging.

Cerebral Headquarter Location

340 S Lemon Ave #9892

Walnut, California, 91789,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Cerebral

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Cerebral in 3 CB Insights research briefs, most recently on Oct 26, 2021.

Expert Collections containing Cerebral

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cerebral is included in 4 Expert Collections, including Mental Health Tech.


Mental Health Tech

1,215 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.


Unicorns- Billion Dollar Startups

1,168 items


Digital Health

13,070 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)



2,833 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

Cerebral Patents

Cerebral has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Application Date


Grant Date


Related Topics



Latest Cerebral News

InnovationRx: FTC Investigating Cerebral; Plus, FDA Panel OKs Vaccines For Young Kids

Jun 16, 2022

New!Follow this author to improve your content experience. Got it! Got it! InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here . M ental health startup Cerebral is being investigated by the Federal Trade Commission regarding possible deceptive and unfair advertising and marketing practices, The Wall Street Journal reported on Tuesday evening. In an email, Cerebral spokesperson said the company was “cooperating with the FTC” and “has no additional comment.” According to the Journal, the FTC specifically inquired about Cerebral’s subscription billing policies. Last year, the federal agency said it was stepping up enforcement against companies that “trick or trap consumers into subscription services.” Cerebral, valued at $4.8 billion in a funding round led by SoftBank last year, offers monthly automatic recurring subscriptions for medication and therapy for mental health conditions, including ADHD, anxiety and depression. Cerebral charges customers upon registration and “there are no refunds regardless of whether Services were utilized,” according to the company’s publicly available terms and conditions . In February, Forbes reported that Cerebral’s internal refund policies differed from what was publicly posted and outlined 12 scenarios in which the company would grant a full refund, including customer threats of legal action or negative reviews. From a regulatory enforcement standpoint, one of the key issues is that customers understand the material terms of the transaction. The company is also facing a DOJ investigation over its prescribing practices around controlled dangerous substances, including Adderall. The company has said it is cooperating with the DOJ investigation and has no additional comment. On June 8, two Cerebral customers filed a class action lawsuit in U.S. District Court for the Northern District of California (Cherie Debono and Victoria Barber v. Cerebral, Inc.) alleging the company violated California’s automatic subscription renewal law, as well as false advertising and unfair competition laws. Both customers alleged difficulties in canceling their subscriptions. A company spokesperson said “Cerebral cannot comment on any pending litigation.” As of February, Cerebral’s terms and conditions outlined that customers waived their rights to resolving disputes in a court of law, including class actions, and agreed to binding arbitration. However, sometime in the past four months, the company added a 30-day right to “opt out” of binding arbitration and the class action waiver. A Cerebral spokesperson would not comment on when the terms were changed. As Feds Probe Pharma’s Middlemen, Capital Rx Raises $106 Million For Software-Driven Fix Capital Rx cofounder and CEO AJ Loiacono. Capital Rx The Federal Trade Commission took aim at the prescription drug middlemen known as pharmacy benefit managers last week, announcing an inquiry into the opaque system of rebates, claw backs and other financial wizardry that determines how much patients end up paying at the pharmacy counter. The timing couldn’t be better for AJ Loiacono, the cofounder and CEO of Capital Rx, who has spent the past five years building price transparency and claims processing software for this moment. On Monday, New York-based Capital Rx announced it has raised $106 million in Series C funding led by B Capital Group, which brings the company’s total funding to $175 million since launching in 2017. Read more here. Deals Of The Week Billion Dollar Fund: Third Rock Ventures said Wednesday it has raised $1.1 billion for its Fund VI. The Boston-based biotech firm has invested in companies, including Foundation Medicine, which was acquired by Roche for $2.4 billion, and Thrive Earlier Detection, which was acquired by Exact Sciences for $2.15 billion, as well as now public companies like Editas Medicine and Magenta Therapeutics. Third Rock has raised $3.8 billion and invested in 60 companies. Cash-Pay Care: Sesame, a cash-pay healthcare marketplace connecting patients and providers, has raised a $27 million Series B round led by GV. By forgoing health insurance, the company says it contracts with medical practices at steeply discounted prices amounting to “half of what is typical.” This latest round comes a little over a year from its $24 million Series A . Extension For H1: Global healthcare data startup H1 has raised a $23 million extension , following its $100 million Series C announced in November , pushing the company’s valuation to $773 million. “In a time of volatile markets when many are struggling to secure funding, this extension is a vote of confidence in our ability to advance our mission,” cofounder and CEO Ariel Katz, an alum of the Forbes 30 Under 30 Healthcare list, said in a statement. Noteworthy The number of abortions carried out in the U.S. rose in 2020 to 930,160 after hitting a 44-year low in 2017, according to a new report from the Guttmacher Institute. The European Union will buy 110,000 monkeypox vaccines from Danish biotech Bavarian Nordic as the global outbreak grows. Cara Care, a digital therapeutics startup focused on gastrointestinal health, has raised $7 million in a Series A Extension round, as the Germany-based company looks to move into the U.S. and other European markets. Epic Systems founder and CEO Judy Faulkner takes the number two spot in the annual Forbes America’s Self-Made Women List . Health insurer Anthem, which is rebranding to Elevance Health at the end of this month, is renaming its healthcare services unit “Carelon” and is bringing back “Wellpoint” for certain government-subsidized health insurance products. Coronavirus Updates T oday was another step forward in the push to get Covid vaccines to kids under age 5. An FDA advisory committee voted unanimously to recommend Pfizer-BioNTech and Moderna’s Covid-19 vaccines as safe and effective for young children. Forbes’ Madeline Halpert reports the panel OKed Moderna’s two-dose vaccine for children 6 months to 5 years and Pfizer’s three-dose vaccine for children 6 months to 4 years of age. So what’s next? The FDA considers the panel’s recommendations and whether to grant emergency use authorization. Then it heads to the CDC, where director Rochelle Walensky needs to give the final sign-off. The White House has already indicated it expects vaccines for this age group could start to be available as soon as next week. Can We Eradicate Covid? Probably Not. An Infectious Disease Doctor Explains The Challenges We have learned over time that Covid vaccine immunity is short-lived and requires boosting to maintain protection. Los Angeles Times via Getty Images Dr. Mark Kortepeter explains the differences between smallpox, which was eradicated in 1980, and Covid-19 and why the virus is most likely here to stay. Read more here . Other Coronavirus News A previous Covid infection provided more "durable" protection against the omicron variant than two or three doses of Pfizer or Moderna's vaccines, but protection was strongest after both vaccination and an earlier infection , according to a study published Wednesday. Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, tested positive for Covid-19 on a rapid antigen test Wednesday, the agency said.

Cerebral Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cerebral Rank

  • When was Cerebral founded?

    Cerebral was founded in 2019.

  • Where is Cerebral's headquarters?

    Cerebral's headquarters is located at 340 S Lemon Ave, Walnut.

  • What is Cerebral's latest funding round?

    Cerebral's latest funding round is Series C.

  • How much did Cerebral raise?

    Cerebral raised a total of $462M.

  • Who are the investors of Cerebral?

    Investors of Cerebral include WestCap Group, Access Industries, Artis Ventures, Prysm Capital, SoftBank Group and 9 more.

  • Who are Cerebral's competitors?

    Competitors of Cerebral include Minded, Big Health, Brightside, Lemonaid, Spill App and 11 more.

You May Also Like


Brightside offers mental health treatment including deliverable medication and digital CBT, with the support of a dedicated doctor at every step.

Headspace Logo

Headspace develops an online membership platform offering free guided meditation and mindfulness to feel happier, sleep better and beat stress.

Calm Logo

Calm provides a relaxation and self-improvement service accessible through its website and mobile application. Calm offers a free app but also has a paid subscription offering which provides customers with access to a full library of meditation, music and sleep content.

Happify Logo

Happify is a LifeTech company that delivers digital therapeutics and care delivery models to improve mental and physical health. Happify Health’s safe, effective digital tools use scientific research from positive psychology, CBT, and mindfulness, combined with a gamified approach and technology, to impact everyday lives. Happify Health's clinically-validated platform provides global access to a comprehensive, evidence-based intervention catalog.

Lyra Health Logo
Lyra Health

Lyra Health provides mental health benefits for employees and dependents. Lyra Health uses matching technology and digital platform, Lyra connects companies and their employees-plus spouses and children-to therapists, mental health coaches, and personalized medication prescribing.

Unmind Logo

Unmind operates as a workplace mental health platform. The platform offers scientifically-backed tools and training for healthier, happier, more human organizations.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.